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Abstract

The landscape of cancer care has changed dramatically over the past several decades. An
illness that was once often fatal, now represents both an acute life threatening illness and
a chronic condition. While there have been tremendous advancements in the treatment of
the physiological aspects of cancer, management of related psychosocial and emotional
issues have not seen this same progress. Limited information exists related to both the
evaluation and outcome metrics associated with the screening and management of
psychiatric sequelae after referral to specialized psychiatric services in cancer patient
populations. This capstone project focused on (a) implementation of consistent use of the
Patient Health Questionnaire 9-item (PHQ-9) survey for patients seeing a provider in the
Norton Cancer Institute Behavioral Oncology Program (NCIBOP) at each outpatient
visit, (b) assessment of patient outcomes for changes in depression scores, (c) review of
clinical interventions by providers, and (d) identification of opportunities for integration
of psychiatric practice guidelines. Evidence-based practice guidelines were incorporated.
The major findings were sequential assessment paired with evidence-based interventions
lead to statistically significant reduction in PHQ-9 and Distress scores.
Keywords: depression, distress, anxiety, coping, stress, cancer, psychosocial
support, neoplasms, oncology, psychosocial support, psychotherapy, psychiatry,
interventions, groups, quality of life, quality, outcomes, insurance, mental health
coverage and patient education
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Introduction
In 2007, the Institute of Medicine (IOM) released a report, Cancer Care for the
Whole Patient: Meeting the Psychosocial Health Needs, which underscored the
importance of integrating mental health specialists into the care of cancer patients. It is
reported that one in ten individuals have someone in their family dealing with cancer. In
addition, it is projected that 40% of the United States population will receive a cancer
diagnosis at some point (IOM, 2007; Meijer et al., 2011). Preliminary secondary analysis
of the National Health and Nutrition Examination Survey (NHANES) 2003-2008 data
revealed significant findings: (a) 9.5% of individuals with cancer meet criteria for Major
Depression compared to 7.5% of non-cancer patients, (b) more cancer patients report
moderate symptoms of depression (10.2% versus 7.1% respectively), and (c) cancer
patients express more depressive symptoms (3.3 compared to 2.9) (Loprinizi & ArcherNanda, 2013).
While the importance of emotional and psychological care is known, access to
specialized psycho-oncology providers is limited, even absent in some institutions
(Ferrell, 2005), placing responsibility to care for emotional needs on the medical team,
nursing staff, and family caregivers. Among practices that do monitor for psychological
distress and refer to specialized psychiatric providers, few have implemented systematic
assessments of depression with valid and reliable tools (Carlson, Waller, Groff, Zhong, &
Bultz, 2012; Jacobson, 2012). Opportunities exist to incorporate quality and outcome
metrics associated with the screening and management of psychiatric sequelae in
specialized psycho-oncology practices (Carlson et al., 2012).
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Despite the importance of evidence-based care, there have been few studies
addressing such interventions in the cancer patient population (Berard, 2001). This paper
(a) describes the prevalence of depression in cancer patient populations, (b) explores the
impact of untreated psychological and emotional sequela, (c) outlines a process
improvement plan, and (d) defines quality metrics for the systematic assessment of
depression in patients seen within an embedded psycho-oncology program. This paper
reviews the integration of evidence-based practice guidelines.
Background and Significance
Adaptation to Illness
At the onset of a cancer diagnosis, patients and families are faced with the
challenge of adapting to a new illness and making a number of adjustments to meet the
demands of the diagnosis. Growing improvements in the areas of early detection and
prevention have changed the landscape of cancer from a disease that had been fatal in
many instances to what is now a variety of different illnesses with a good prognosis and
even potential for cure (IOM, 2007). With the myriad of treatment options available to
cancer patients including chemotherapy, radiation therapy, and surgery, two-thirds of
cancer patients live at least five years (Meijer et al., 2011). Despite the advancements in
the physiological aspects of cancer treatments, the availability of treatment focusing on
the psychological, social, and emotional aspects of cancer care have not kept pace (IOM,
2007). Although psychological distress is common in cancer patients, it often goes
unrecognized and untreated (Berard, 2001; Bottomley, 1998; Dalton et al., 2009; Hopko
et al, 2008; Luutonen, Vahlberg, Eloranta, Hyvari, & Salminen, 2011; Meijer et al., 2011;
Newport & Nemeroff, 1998; Ryan et al., 2005; Shimizu et al., 2010).
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Adaptation to a new normal within the context of cancer presents many
challenges including financial, emotional, and knowledge based stressors (IOM, 2007).
Patients face many obstacles that may preclude successful anti-cancer efforts. Among the
most significant barriers cancer patients report are financial problems, inadequate or
absence of health insurance, poor communication with physicians, and lack of
psychosocial care (IOM, 2007). Each of these barriers has the potential to adversely
impact health outcomes (IOM, 2007). It is reported up to one-third of cancer patients
experience persistent distress, which may even interfere with treatment (Sellick &
Edwardson, 2007; Singer et al., 2008). Fewer than half of patients who need psychiatric
treatment receive this care (Fromer, 2006).
Prevalence of Depression in Oncology Patients
Among psychological and emotional comorbidities in cancer patient populations,
depression has received the most attention (Massie & Greenberg, 2004). Although more
than 150 studies exist describing the prevalence of depressive disorders, this data has
wide variability due to inconsistent methodology and differing inclusion criteria of
depressive disorders (Dalton et al., 2009; Massie, 2004; Massie & Greenberg, 2004;
Salvo et al., 2012). Prevalence data on depression in cancer patients ranges up to 60% in
studies. There is clinical agreement that approximately 25% of cancer patients will
experience a depressive episode resulting in the need for depression management
(Bottomley, 1998; Massie, 2004; Pirl & Roth, 1999). This statistic becomes even more
remarkable when compared to Meijer and colleagues (2011) report that the prevalence of
depression in the general population is approximately 6%.
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From an epidemiological perspective, enhanced understanding of cancer patient
risks for depression and other psychological sequelae has potential to propel the inclusion
of mental health interventions as a standard part of care onto the national agenda. There
are no known epidemiological studies available describing the cancer patient’s increased
risk for depression, when compared to the general population using the NHANES data in
the United States.
Systematic Assessment of Depression in Oncology Practices
The diagnosis of depression can be easily overlooked and assumed by cancer
clinicians to be an adaptation to illness with minimization of depression severity (Massie
& Greenberg, 2004; Mystakidou et al., 2008). Since adaptation to illness can be enhanced
through psychosocial interventions, screening individuals to determine the need for a
psychiatric referral is an important component of care. Multiple studies have documented
the importance of screening for and identifying patients at high risk for emotional distress
(Bottomley, 1998; Holland et al., 2005; Hopko et al., 2008; McCorkle, Pasacreta, & Tuzh
Tang, 2003; Meijer et al., 2011; Newport & Nemeroff, 1998; Norris, Pratt-Chapman,
Noblick, & Cowens-Alvarado, 2011; Ransom, Jacobson, & Booth-Jones, 2006; Ryan et
al., 2005; Salvo et al., 2012; Sellick & Edwardson, 2007; Shim, Shin, Jeon & Hahm,
2008; Shimizu et al., 2012; Smith et al., 2009; Thewes, Meiser, Tucker, & Scnieden,
2003; Vahdaninia, Omidvari, & Montazeri, 2010; Zabora, BrintzenhofeSzoc, Curbow,
Hooker, & Piantadosi, 2001). Despite this evidence, screening for distress in this
population is still not consistently done, with estimates that less than half of patients with
distress are identified (Sellick & Edwardson, 2007). As few as 10% of patients are
referred for specialty care with psycho-oncology providers, therefore limiting
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opportunities to improve quality of life, treatment adherence, and potentially prognosis
(Smith et al., 2009; Vahdaninia et al., 2010).
There are few specialty-trained providers equipped to address the psychological
and emotional needs of cancer patients. Although there is a significant body of literature
supporting the psychological care for cancer patients, there is a gap with respect to
program availability and practice (Greenberg, 2004; Pengelly & Purnell, 2009;
Weinberger, Bruce, Roth, Breitbart, & Nelson, 2010). In recognition of this need, there
are emerging models for enhancing collaboration between mental health and medical
health homes (Druss & Mauer, 2010; Rhodes, Vieth, Kushner, Levy, & Asplin, 2009).
Evidence-Based Care
Since the release of the IOM Report, Crossing the Quality Chasm in 2001,
emphasis has been placed on ways healthcare systems can improve care. The report
identified safety, patient centeredness, effectiveness, timeliness, efficiency, and equality
as six overarching aims to better meet patient needs (IOM, 2001; Stanik-Hutt et al.,
2013). Quality is representative of clinical interventions and patient perceptions of care
that are both safe and effective (Stanik-Hutt et al., 2013). Implementation of processes
and structured care interventions has the opportunity to improve quality and ultimately
outcomes (Stanik-Hutt et al., 2013).
The integration of evidence-based practice guidelines in clinical settings is one
approach to minimizing broad variation in care delivery across clinicians (IOM, 2001;
Oldham, Golden, & Rosof, 2008; Wobrock, Weinmann, Falkia, & Gaebel, 2009).
Depression remains one of the most prevalent and treatable mental health disorders
(Kroneke, Spitzer, & Williams, 2001). One approach to enhance quality in psychiatric
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practices is through use of valid and reliable patient questionnaires to assess patient
outcomes (Oldham et al., 2008; Valenstein et al., 2004). Among depressed adults,
medications and psychotherapy are both evidence-based interventions for treatment and
management (Agency for Health Care Research and Quality [AHRQ], 2009; American
Psychiatric Association [APA], 2010, 2012; Katon & Schulberg, 1992; O’Connor,
Whitlock, Beil, & Gaynes, 2009).
Still, Oldham and colleagues (2008) have highlighted that psychiatry struggles as
a discipline to adhere to evidenced-based treatment guidelines. Lack of awareness
regarding guidelines, complexity of bio-psycho-social interactions, absence of psychiatric
providers by region, and challenges to healthcare systems have all contributed to the
underutilization of clinical practice guidelines (Oldham et al., 2008; Wobrock et al.,
2009). As a result, mental health interventions are often without an evidence-based
approach despite the known importance of delivering effective and scientifically based
care (Aarons, 2004).
Improved care from systematic assessment. One systematic review of
outcomes resulting from screening for depression in cancer patients exists (Meijer et al.,
2011). The study authors identified nineteen studies addressing accuracy of screening
including one trial evaluating treatment efficacy for Major Depression. No trials
specifically examined changes in outcomes based on the implementation of screening
alone (Meijer et al., 2011). McMillan, Small, and Haley (2011) conducted a study that
showed standardized systematic assessment of depression by interdisciplinary teams
among cancer patients enrolled in hospice care was associated with significant
improvement in depression and quality of life. Complicating the issue of systematic
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assessment in cancer patient populations is the lack of consensus among psychooncology providers regarding which psychometric instrument is most appropriate for use
in this patient population.
Policy Support for the Integration of Psychosocial Assessment and Management
At a national level the Commission on Cancer (CoC) is tasking oncology
practices with finding ways to implement distress screening and referral to specialized
psychosocial providers by 2015 (CoC, 2012; Edge & Bura, 2011; Jacobson, 2012).
Through collaboration and oversight since the 2007 IOM report, efforts have expanded to
include the provision of psychosocial screening and the addition of mental health
providers to deliver this specialty care. With the support of multiple organizations,
including the American Psychosocial Oncology Society (APOS), the National Quality
Forum (NQF), the CoC and the American College of Surgeons (ACoS), the International
Psychosocial Oncology Society (IPOS), and the Quality Oncology Practice Initiatives
(QOPI), the importance of quality mental and emotional health interventions in cancer
populations will continue to stay on the national agenda. Current QOPI metrics require
the identification of emotional needs by oncology providers (QOPI, 2012).
In order to sustain and grow psychiatric programs within oncology practices, the
identification of appropriate evaluation metrics is an important step that becomes even
more urgent as our healthcare environment continues to change. Gaps exist in the cancer
psychiatry literature related to the specific role of depression screening and process
improvement initiatives for depression management in cancer patient populations. At the
study site, Norton Cancer Institute (NCI), oncology providers assess for distress using the
Distress Thermometer (DT) (Appendix A). Oncology providers then refer patients with
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psychiatric needs for specialized mental health assessment by the providers. After referral
to NCIBOP, an opportunity existed to implement systematic use of the PHQ-9 survey
(Appendix B). The goal of this quality improvement project was to improve patient
outcomes through sequential monitoring of depression with the PHQ-9 survey and the
delivery of evidence-based treatment approaches.
Purpose
The purpose of this quality improvement capstone project was to (a) implement
the PHQ-9 survey at each visit for patients seeing a provider in the NCIBOP, (b) assess
patient outcomes for changes in depression scores, (c) review clinical interventions by
providers, and (d) identify opportunities for integration of psychiatric practice guidelines.
Review of the Literature
A search of the databases Academic Search Premier, Cumulative Index of
Nursing and Allied Health Literature (CINAHL), MEDLINE, PsychINFO, Psychology
and Behavioral Sciences Collection and Newspaper Source was conducted. A
combination of key words was used, in addition to appropriate subject terms including
social support, psychiatry, depression, distress, anxiety, coping, stress, cancer,
psychosocial support, neoplasms, psychotherapy, interventions, groups, quality of life,
quality, outcomes, insurance, mental health coverage and patient education. References
of selected studies were inspected for additional related papers. Dates were not specified
for review based on the limited availability of relevant papers. Selection criteria included
studies addressing the significance of psychosocial needs in cancer patients, screening
and quality indicators related to the psychosocial care of cancer patients. Experts in the
area of psycho-oncology were contacted for information. The recent IOM reports
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addressing care for the whole patient, quality mental health care and crossing the quality
chasm were also used for the purposes of this review.
Significance of Psychosocial Needs in Cancer Patients
Prevalence. Cancer patients report significantly higher levels of distress than
individuals in the general population and are at increased risk for mental health problems
including depression and anxiety disorders (Bottomley, 1998; Corboy, McDonald, &
McLaren, 2011; IOM, 2007; Jehn et al., 2012; Trinidad, Simopoulous, & Flosnik, 2011).
The risk for depression in cancer patients is reported to be four times greater than in the
general population (Blake-Mortimer, Gore-Felton, Kimerling, Turner-Cobb, & Spiegel,
1999; Bowers & Boyle, 2003; Massie & Greenberg, 2004; White & Macleod, 2002).
Depression is reported as the number one psychiatric co-morbidity and is consistently
rated as one of the ten most distressing symptoms for cancer patients, affecting up to 60%
of patients during their illness (Badger, Braden, & Mishel, 2001; Bowers & Boyle, 2003;
Breitbart, 1994; Fafouti et al., 2010; Hopko et al., 2008; Hosaka, Sugiyama, Tokuda, &
Okuyama, 2000; Jehn et al., 2012; Massie & Greenberg, 2004; Montgomery, Pocock,
Titley, & Lloyd, 2003; Pirl, 2004; Ross, Boesen, Dalton, & Johansen, 2002; Salvo et al.,
2012; Spiegel & Giese-Davis, 2003; Spiegel et al., 1999; Spijker, Trijsburg, &
Duivenvoorden, 1997; White & Macleod, 2002). During advanced stages of illness the
incidence of depression increases from 20-25% to 50-70% (Bowers & Boyle, 2003:
Breitbart, 1994).
Risk of undiagnosed depression. Mood disturbances such as anxiety and
depression are often viewed as normal responses to a serious diagnosis like cancer
(Massie & Greenberg, 2004; Spiegel & Giese-Davis, 2003) and have been identified as
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the most common psychiatric comorbidities in cancer populations (Jehn et al., 2012;
Salvo et al., 2012). Expected cognitive and behavioral responses often mask depression,
causing it to remain undiagnosed and untreated in up to 80% of patients (Lloyd-Williams
& Riddleston, 2002). There is a disparity between the number of patients experiencing
psychological co-morbidities and the number of patients receiving appropriate referrals to
specialized psychiatric providers.
A systematic review of psycho-oncology literature reported 29% of cancer
patients experienced depression (Hotopf, Chidgey, Addington-Hall, & Ly, 2002; Salvo et
al., 2012). Researchers examining the prevalence of depression found that 29% of 524
patients screened were depressed, a value two times greater than for non-cancer patients
(Gruneir, Smith, Hirdes, & Cameron, 2005). Interestingly, these individuals were also
less likely to receive antidepressant therapy (Gruneir et al., 2005). Only 30% received
antidepressants and only 20% were seen by a mental health professional (Gruneir et al.,
2005). Remarkably, cancer patients who were not depressed were more likely to be
followed by a psychiatric provider than those with clinical depression (Gruneir et al.,
2005).
Hwang and colleagues (2004) in a study of veteran patients, found higher levels
of psychological distress to be associated with an overall sense that needs were not being
met across the care spectrum. In another study of long-term cancer survivors, those with
higher levels of distress remembered their experience as more negative, with more
challenges both physically and psychologically (Maliski, Sarna, Evangelista, & Padilla,
2003).
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Houts and colleagues (1986) assessed areas of unmet need during cancer
treatment in both patients and caregivers. The most frequently reported unmet need was
emotional problems reported by 25% of respondents (Houts et al., 1986). In a
comparative study, Barg and associates (2007) used qualitative interviews to assess the
continuance of unmet psychosocial needs. Two-thirds of these respondents reported one
or more unmet psychosocial need during treatment (Barg et al., 2007). Psychological
needs have been found to be second only to assistance with daily living with cancer
patients rating psychological needs higher than information or other support needs
(Sanders, Bantum, Owen, Thornton, & Stanton, 2010). These studies indicate that
although efforts exist to ameliorate distress in cancer patients and meet the psychosocial
needs of patients, there is still a lot of work to be done (Barg et al., 2007; Houts et al.,
1986; Sanders et al., 2010).
Biopsychosocial factors associated with depression in cancer patients.
Shimizu and colleagues (2012) presented findings from the largest study to date
examining biopsychosocial risk factors for the development of depression in lung cancer
patients. These researchers found that patients who reported low fighting-spirit,
hopelessness/ helplessness, anxious preoccupation, and high scores for neuroticism were
all at increased risk for development of depression (Shimizu et al., 2012). Patients with a
tendency for neuroticism contribute to burden on medical systems, increase medical costs
and have increased risk for depressive illness (Cuijpers, Smit, Penninx, de Graaf, &
Beekman, 2010; Shimizu et al., 2012). These studies indicate the significance of unmet
emotional needs in patients with cancer and their caregivers.
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Consequences of Unmet Psychosocial Needs
Left untreated, unmet psychological and emotional sequelae have significant
consequences. Psychological impairment and the presence of mental health problems
including depression, anxiety, post-traumatic stress symptoms (PTSS), and posttraumatic stress disorder (PTSD) contribute to role impairment, reduced compliance with
medical treatments, reduced quality of life, increased medical costs, prolonged
hospitalizations, higher utilization of medical care, impacts symptom severity, and poor
medical outcomes (Akechi et al., 2003; Badger el al., 2001; Bowers & Boyle, 2003;
Breitbart, 1994; Greneir et al., 2005; IOM, 2007; Kissane, 2009; Montgomery et al.,
2003; Newport & Nemeroff, 1998; Passik & Breitbart, 1996; Pirl & Roth, 1999; Ransom
et al., 2006; Ryan et al., 2005; Salvo et al., 2012; Sellick & Edwardson, 2007; Shimizu et
al., 2012; Spiegel & Giese-Davis, 2003; Thewes et al., 2003; Valente & Saunders, 1997).
In addition, failure to assess depression in cancer patients ignores depression as a
treatable illness and inadequately attributes depression as a possible result of a deeper
physiological process that may need further evaluation (Akechi et al., 2003; Bowers &
Boyle, 2003; Breitbart, 1994; Greneir et al., 2005; Massie & Greenberg, 2004;
Mystakidou et al., 2008; Passik & Breitbart, 1996).
Depression contributes to impairment in personal, social, occupational, and family
functioning (Dalton, Laursen, Ross, Mortensen, & Johansen, 2009; Hopko et al., 2008;
Wobrock, Weinmann, Falkai, & Gaebel, 2009). Untreated distress and lack of available
psychosocial support place families at risk for role strain and impairment in family
functioning (Akechi, et al., 2007; Salvo et al., 2012; Vahdaninia, Omidvari, & Montazeri,
2010). As distress exists along a continuum, waiting until severe levels of distress occur,
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fails to provide timely care that could prevent catastrophic results (Paterson et al., 2001).
In severe cases, depression may even lead to an enhanced desire for sooner death or
suicide (Akechi et al., 2007; Breitbart et al., 2000; Chochinov et al., 2005; Greneir et al.,
2005; Hooper, Vaughan, Tennant, & Perez, 1997; Kugaya et al., 1999; Suarez-Almazor,
Newman, Hanson & Bruera, 2002).
Cancer patients are at increased risk for suicide. Many factors contribute to this
increased risk including pain, physical symptoms, advanced illness with poor prognosis,
depression resulting in hopelessness, delirium and disinhibition, loss of control and
helplessness, preexisting psychopathology, suicidal history, and inadequate social support
(Akechi et al., 2010; Breitbart, 1994; Massie & Greenberg, 2004). Patients suffering
severe depression are at risk for a desire for sooner death, suicide, and may even request
physician-assisted suicide (Akechi et al., 2010; Blake-Mortimer et al., 1999; Greneir et
al., 2005; Shimizu et al., 2012).
Individuals with cancer and concurrent depression and anxiety have more
difficulty with somatic concerns, disability, more unexplained symptoms, and increased
symptom severity (Greneir et al., 2005; IOM, 2007; Shimizu et al., 2012). Co-morbid
psychiatric illnesses have been associated with unhealthy behaviors and reduced
adherence to anti-neoplastic treatments (Greneir et al., 2005; IOM, 2007). Distress can
contribute to a reduced level of hope, thus translating to a belief that cancer treatments
are not worthwhile and contributing to poor follow-through with potentially curative
treatments. Optimism relates to an underlying capacity for resilience, which lends to
greater ability for problem solving, enhanced coping strategies, and an ability to find
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meaning in illness (IOM, 2007). The presence of psychological distress reduces these
functions and increases the risks of possible long-term complications (IOM, 2007).
Screening for Depression using the PHQ-9
In efforts to improve quality healthcare for mental health conditions, the IOM
(2006) recommended clinicians use reliable and valid patient questionnaires routinely to
assess progress and outcomes in patients. An extensive database of psychometric scales
exists within the field of psychiatry. However, further research is needed within the field
to strengthen the recommendation toward a single tool (Wobrock et al., 2009). A wellstudied, reliable, and valid tool for the measurement of depression is the PHQ-9 (Arroll et
al., 2010; Dominquez-Rafer & Lin, 2011; Kronke et al., 2001). The PHQ-9 is a brief tool
that is used with medically complex patient populations, including the cancer patient
population (Fann et al., 2009; Manea, Gilbody, & McMillan, 2012; Oromo, Fann,
Weymuller, Macharia, & Yueh, 2006; Thekkumpurath et al., 2011). Using a cut-off score
of greater than or equal to 8, Thekkumpurath and colleagues (2011) reported the PHQ-9
to be 93% sensitive and 81% specific. There is currently no benchmark data related to use
of the PHQ-9 in cancer patient populations. An opportunity exists to establish
benchmarks within the field of psychiatry and psycho-oncology. Studies detailed in this
paper including the PHQ-9 and sequential assessment of depression are included in the
literature matrix in Appendix C.
The PHQ-9 is a brief scale by comparison to many other depression measures and
consists of the criteria on which the diagnosis of depression is based, making this tool
partner well with a clinical interview (Kroenke & Spitzer, 2002; Rodin et al., 2006). The
NQF endorses outcome measurements for mental health, including measures that focus
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on depression and the use of standardized psychometric scales, specifically the PHQ-9
(2011). Epidemiological studies including NHANES and Behavioral Risk Factor
Surveillance System (BRFSS) use the patient health questionnaire series (PHQ-8/9) for
assessment of depression to gather national study data (Centers for Disease Control
[CDC], 2012; NHANES, 2013).
Current practice with psychometric scales. Currently broad variability exists
among measurements used in psychiatry and psycho-oncology departments. The IOM
report (2006) describes that as few as 27% of studies reviewed showed adherence to
clinical guidelines and as few as 10.5% of individuals were found to receive evidencebased interventions. A recommendation exists for patient centered decision-making and
engagement in care, including information regarding options for and effectiveness of
treatments (IOM, 2006).
A better understanding of a patient’s baseline presentation allows for ongoing
assessment of interventions and identifies opportunities to focus on targeted areas for
clinical improvement (Oldham et al., 2008). The methodology and implementation of
quality improvement initiatives within the mental health arena is in its very early stage of
development. A dearth of information exists within the mental health community with
regard to consistently used metrics and benchmarking to assess clinical and functional
outcomes (Hermann, Leff, & Lagodmos, 2002; Valenstein et al., 2004). A gap remains
between clinical care and evidence based practice guidelines (Hermann et al., 2006; IOM,
2006). The APA endorses pharmacotherapy, supportive psychotherapy, and combined
medication management and psychotherapy as efficacious in depressed patients (2010,
2012). After integration of evidence-based practice interventions within practices,
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anticipated outcomes include improvement in depressive symptoms, reduced recurrence
risk, and reduction in depression related morbidity and mortality (APA, 2010).
Theoretical Framework
Many factors influence an individual’s ability to react to stressful situations
including culture, ethnicity, personal history, and even personality (Folkman &
Moskowitz, 2004; Garland & Bush, 1982). A theoretical structure assists our
understanding of the complexities of coping and how individuals manage internal and
external stressors (Folkman & Moskowitz, 2000; Folkman & Moskowitz, 2004). Within
the theoretical model of stress and coping, it becomes possible to appraise the value an
individual attributes to events, while also determining how the individual manages these
events (Lazarus & Folkman, 1984; Folkman & Greer, 2000). This understanding provides
a foundation for the promotion of psychological well-being through exploration of
meaning, goal creation, and determination of patient perspective (Folkman & Greer,
2000).
Individual adaptation to illness exists along a continuum (Holland & Freelander,
2006; Lazarus, 1974). The integration of illness-related factors and disease specific
interventions impact individual coping. A myriad of coping mechanisms are necessary as
an individual undergoes cancer treatment. Identification of patients with concurrent
mental health disorders provides insight to individuals who may be at risk for impaired
coping. Sequential assessment of depressive illness provides a measurement at several
points in time and may provide insight to psychological and emotional adaptation as it
occurs over time. Enhancement of coping strategies provides benefit to patients and
minimizes weakened problem solving.
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Methods and Procedures
Model of Evidence-Based Practice
This pilot project implemented routine assessment with the PHQ-9 to illustrate
changes in the patients’ subjective experience. The PHQ-9 was obtained prior to the
initiation of treatment and at each follow up appointment with NCIBOP providers to
ascertain changes in patient symptoms. Providers in the department were educated on
evidence-based practice interventions as part of the preparation for this quality
improvement project. In an effort to reduce treatment variability, evidence-based
interventions and best-practice guidelines were incorporated consistently among
providers. Though it was beyond the scope of this pilot project, ongoing data tracking has
continued to occur for the identification of additional practice improvement initiatives.
Baseline data obtained through this process and quality improvement project are
described in Appendix D.
Intervention and Implementation Timeline
The implementation of this process and quality improvement project consisted of
a number of phases (see Appendix E) leading up to this capstone project completion.
Regular meetings began in August 2012 with the physician leader in the department, the
Director of Quality, CNO, and NCIBOP team to provide education, rationale for
sequential assessment with the PHQ-9, and evidence-based treatment guidelines. Initial
exploration of the NCIBOP as a microsystem in September 2012 provided an in-depth
understanding of the department characteristics, patient population, departmental
processes, and preliminary departmental outcome data. Limited availability of outcome
data reinforced the need to operationalize departmental processes and capture outcomes.
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A comprehensive review of the literature identified the implementation of routine
psychometric assessment with the PHQ-9 as an acceptable approach to understand
outcomes and integrate evidence-based practice interventions. As the Norton Healthcare
(NHC) system transitioned to the new EMR, EPIC, the PHQ-9 was incorporated into the
visit navigator for NCIBOP providers. Initial discussion of implementing the PHQ-9 at
initiation of care and regular intervals began in September 2012. To ensure availability of
the PHQ-9 in the EMR, routine meetings were held with the ISA/IT team.
Departmental processes to include the PHQ-9 at initial and follow up visits began
in January 2013. As this project-necessitated considerable pre-work, the capstone project
was initially discussed with the chair and committee members in October 2012. This
capstone project was formally proposed and approved by the capstone committee in May
2013. Ongoing visits were made to clinical managers and support teams throughout this
project to enhance process consistency and sustain support. Regular updates were
provided to NCI leaders to sustain support for the project. Weekly NCIBOP team
meetings continued throughout 2013 to reinforce provider accountability for PHQ-9
entry, documentation of the diagnostic assessment, treatment recommendations
(pharmacological and non-pharmacological), and the plan for follow up care. The project
budget is described in Appendix F.
Setting and Population
NCI is part of the NHC system and has practice sites at each of the four adult
hospitals in Louisville, KY, as well several other locations within Kentucky and Southern
Indiana. The practice employs 35 physicians and 22 advanced practice registered nurses
(APRN) in medical, surgical, gynecological, radiation, orthopedic, neurological, and
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behavioral oncology. The NCIBOP is a fully embedded psychiatric program offering a
spectrum of services to help medically complex patients and families deal with cancer
and related quality of life issues. The program is comprised of one physician, three
advanced practice nurses, a part time social worker, a nurse, and two administrative staff.
A clinical microsystem assessment was completed for the NCIBOP. Chart
reviews of patients seen in the department revealed 59% of patients seen within the
department were diagnosed with and being treated for a depression spectrum disorder.
Consistent with the psycho-oncology literature, depression is the number one mental
health diagnosis within the department.
Sample
Forty-one patients seen for an initial evaluation in the outpatient setting between
January 1, 2013 and March 31, 2013 were included; 107 were excluded. Study
participants included males and females greater than 18 years of age with an oncologic
diagnosis. Individuals seen through the department who did not have a cancer diagnosis
(family members or those with benign disorders), inpatient consultations, and individuals
seen for less than two visits were excluded.
Intervention
Sequential assessment of depression using the PHQ-9 was implemented. The
information technology (IT) team was consulted to build the PHQ-9 template and
synopsis reporting features into the Electronic Medical Record (EMR) to enhance data
aggregation opportunities. PHQ-9 scores were entered into the EMR by the NCIBOP
providers for comparison of subsequent scores against baseline data. Evidence-based
practice guidelines related to the treatment and management of depression were
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disseminated to the provider team. Practice observations and opportunities for enhancing
care with evidence-based interventions were shared with the NCIBOP providers.
Instrument. The PHQ-9 survey is based on the diagnostic criteria for depression
and pairs with a clinical interview to determine the presence of depressive illness
(Kroenke, Spitzer & Williams, 2001; Kroenke & Spitzer, 2002; Lowe, Kroenke, Herzog,
& Grafe, 2004; NQF, 2011; Spitzer, Kroenke & Williams, 1999). The tool consists of 9
questions with scores ranging from zero to three to determine the presence and severity of
depressive illness. Scores 1-5 indicate minimal depression, 6-10 mild depression, 10-14
moderate depression, 15-19 moderately severe depression and 20-27 severe depression
(Kroenke et al., 2001; Kroenke & Spitzer, 2002; Spitzer et al., 1999). Using a cut-off
score of 10 or higher, the tool has a high sensitivity (0.93) and specificity (0.85) and
acceptable positive and negative predictive values (Wittkampf et al., 2009). The PHQ-9
has demonstrated capacity to ascertain depression outcomes (Lowe et al., 2004). This tool
is simple and cost-effective. The PHQ-9 is a free resource with no copyright or
distribution restrictions. This one-page screening tool was acceptable and easy for both
patients and clinicians to use.
Data Collection
New patient charts were reviewed for the presence of documentation of the PHQ9 in the EMR. Data was gathered on all newly referred patients to the NCIBOP meeting
inclusion criterion from January 1, 2013 through March 31, 2013. A six-month
retrospective chart review concluded September 30, 2013. Data was de-identified to
maintain patient privacy.
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Data aggregation was an ongoing process; the PI analyst and the department
manager shared responsibility for data collection with quality assurance checks to ensure
data integrity. Socio-demographic data included age, gender, race, ethnicity, educational
level, religious affiliation, marital status, and employment status. Clinical data included
cancer type and stage. Socio-demographic and clinical data were extracted from patient
charts. Provider documentation in the EMR was reviewed for (a) PHQ-9 entry at each
visit, (b) psychiatric diagnosis, (c) treatment plan and rationale (including
psychopharmacological intervention and non-pharmacological interventions), (d) goals of
care, and (e) plan for follow-up care. Data was aggregated and entered into a spreadsheet
for analysis and ongoing observation.
Data Analysis
Data was analyzed using Stata, College Station, TX, version 12.0. Inferential
statistics were run with paired-samples t-test analysis to identify changes in PHQ-9 and
distress scores pre/post NCIBOP intervention. Descriptive statistics were run for analysis
of clinical and socio-demographic data, means (95% Confidence Interval [CI]) were
calculated for continuous variables and proportions (95% CI) were calculated for
categorical variables. Statistical significance was established as p < 0.05. Content
analysis of provider feedback is described.
Approval for Implementation
The study was reviewed by the Western Institutional Review Board (WIRB) and
was granted a waiver of authorization (approval #1140717). The Norton Healthcare
Office of Research Administration (NHORA) approved the study (NHORA #13-N0160).
Required documentation describing the study was filed with Bellarmine University’s
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Institutional Review Board (Non-BU IRB Submission Summary Form). Approval was
received from the departmental providers, the capstone committee, and NCI executive
leadership.
Ethical considerations. This process improvement initiative was implemented to
develop a procedure for sequential assessment with the PHQ-9 at NCIBOP provider
visits. Completion of the PHQ-9 remained voluntary. Patients were educated regarding
the rationale for routine assessment and quality measures to enhance the delivery of
quality care. The Director of Quality and the PI nurse were engaged in data collection and
auditing of study data to ensure maintenance of objectivity.
Evaluation Plan
Using the initial PHQ-9 and subsequent assessment score, the impact of the
implementation of sequential monitoring with the PHQ-9 was measured. Changes in
PHQ-9 scores were considered a measure of clinical effectiveness. Programmatic
outcome metrics were aggregated and ongoing process improvement efforts were
maintained to ensure the continuation of evidence-based treatment approaches.
Aggregated data provided an overview of patient outcomes and reflected a high level of
quality care delivered through the department. Capability to focus on group outcomes
rather than individual outcomes provided an optimal foundation for ongoing departmental
quality improvement initiatives (Dulgacz, 2006; Oldham et al., 2008).
Collateral feedback from providers about the process and utility of the project was
obtained during provider team meetings (Appendix G). The provider team agreed the
PHQ-9 was easy for patients to use, is important to administer routinely, and has been
helpful in guiding treatment decisions.
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Results

Descriptive Analysis
The majority of the sample was married, Caucasian females. The mean age of
participants was 58 (SD=11.3) years of age. On average, patients were seen for 5.5
(SD=3.1) visits. Socio-demographic characteristics are presented in Table 1.
Table 1
Sociodemographic Characteristics of the Study Group (N=41)
Characteristic

n

Proportion (%)

9
32

21.90
78.00

36
2

94.70
5.26

26
5
4
1
3
1

65
12.5
10.0
2.5
7.5
2.5

4
12
11
8
3

10.5
31.5
28.9
21.0
7.8

18
4
9
9

45.0
10.0
22.5
22.5

21
8

72.4
27.5

Gender
Male
Female
Race
Caucasian
African American
Marital status
Married
Divorced
Widowed
Separated
Never Married
Partner
Educational attainment
Some high school
12th grade
Some college
Bachelor’s
Post-graduate
Employment status
Employed
Unemployed
Retired
Disabled
Religions Affiliation
Yes
No
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Cancer diagnostic and staging variables were obtained (see Table 2). Cancer
staging was obtained, however caution should be taken when interpreting this variable.
The medical record did not always clearly describe times of progression or remission.
Table 2
Cancer Associated Characteristics and Staging (N=41)
Characteristic
Cancer Diagnosis
Hematological Malignancy
GI Cancers
Colon Cancer
Brain Tumors
Breast Cancer
Gynecological Cancers
Lung Cancer
Pancreatic Cancer
Head and Neck Cancers
Other
Cancer Stage
Stage 0
Stage I
Stage II
Stage III
Stage IV
Remission

n

Frequency (%)

3
1
3
3
14
6
4
1
1
5

7.3
2.4
7.3
7.3
34.1
14.6
9.7
2.4
2.4
12.1

1
9
13
4
12
2

2.4
21.9
31.7
9.7
29.20
4.80

The most frequent diagnosis among participants was breast cancer (34.1%).
Psychiatric diagnosis was most often reported as Unspecified (36.5%) or Major
Depression (26.8%). Psychiatric diagnosis among study participants is displayed in Table
3. Behavioral Oncology visit process variables included the frequency of completion of
the PHQ-9 across visits.

ASSESSING QUALITY OUTCOMES

27

Table 3
Psychiatric Diagnostic Characteristics (N=41)
Characteristics
Psychiatric Diagnosis
Depression
Major Depression
Unspecified Anxiety
Unspecified Mood Disorder
Bipolar Disorder
Adjustment Disorder with Mixed Features

n

Frequency (%)

15
11
7
4
1
3

36.50
26.80
17.00
9.70
2.40
7.30

At initial evaluation, the PHQ-9 was entered into the EMR 92.6% of the time; at
follow up visits the PHQ-9 was entered 84.1% of the time (Table 4). Table 5 overviews
provider-prescribing. Some patients received more than one psychopharmacological
intervention.
Table 4
Provider Process Variables and Proportions (N =41)
Provider Process Variables
PHQ-9 entered at Initial Evaluation
PHQ-9 entered at Follow Up Visit
Psychiatric Diagnosis Documented
Plan of Care and Rationale Documented
Plan of Care Included Supportive Psychotherapy
Plan of Care Included Medication Management

Proportion (%)
92.68
84.19
100
100
100
89

Table 5
Provider Prescribing Characteristics (N =41)
Prescribing Characteristics
Plan of Care Included Antidepressants
Plan of Care Included Mood Stabilizers
Plan of Care Included Anxiolytic
Plan of Care Included Sleep Aid

n
31
9
20
8

Proportion (%)
75.60
21.90
48.8
19.50
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PHQ-9 and distress intervention analysis.
The forty-one participants pre/post intervention assessments were analyzed for
changes in PHQ-9 scores (total score and individual question scores) and changes in
distress score using the paired samples t-test. Patient initial PHQ-9 scores were compared
with their final PHQ-9 scored. PHQ-9 total mean scores decreased from 11.34 (SD=6.1)
pre-intervention to 8.43 (SD=5.27) post-intervention; this reduction in PHQ-9 total score
was statistically significant (p = 0.0098). All individual PHQ-9 questions showed a
reduction in score post-intervention. Four specific items showed statistically significant
reduction in post-intervention scores: feeling down, depressed or hopeless (p = 0.011),
trouble with sleep (p = 0.01), feeling bad about yourself or that you are a failure or have
let your family down (p = 0.006), and difficulty with psychomotor agitation or retardation
(p = 0.054). In addition, distress scores were significantly reduced after intervention with
NCIBOP providers (p <0.001).
Table 6
Mean Differences in PHQ-9 Total and Item Scores (N = 41)
Indicator
Pre-Intervention Post-Intervention
Total PHQ-9 Score
11.34 (±6.18)
8.43 (±5.27)
Anhedonia
1.20 (±1.00)
1.14 (±0.88)
Depressed
1.51 (±1.07)
1.09 (±0.88)
Sleep
1.80 (±1.16)
1.24 (±1.09)
Fatigue
2.12 (±0.93)
1.70 (±0.96)
Appetite
1.43 (±1.02)
1.21 (±1.15)
Failure
1.02 (±1.25)
0.53 (±0.83)
Concentration
1.24 (±1.11)
0.95 (±1.18)
Psychomotor
0.76 (±0.99)
0.39 (±0.80)
Suicide
0.17 (±0.49)
0.07 (±0.34)
Distress Score
3.80 (±3.68)
0.90 (±1.78)
Note. *p <0.05. **p < 0.01.

t-value
2.71
0.66
2.66
2.68
1.83
1.03
2.91
1.27
1.99
1.16
5.03

p-value
p = 0.009*
p = 0.515
p = 0.011 *
p = 0.011*
p = 0.75
p = 0.311
p = 0.006*
p = 0.209
p = 0.054*
p = 0.253
p = 0.000 **
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Discussion
Evidence-Based Practice Interventions
Previous study has identified variances among cancer patients diagnosed with
depression and those who receive antidepressants (Gruneir et al., 2005). In 2006, the
IOM reported less than 11% of patients receive interventions based on evidence. The
integrated psycho-oncology program in this study implemented a model for evidencebased practice. Providers were accepting of systematic screening with the PHQ-9.
Review of provider documentation revealed adherence to evidence-based interventions;
100% of patient charts reviewed included a psychiatric diagnosis, 89% of patients agreed
to medication interventions for clinical disorders, 100% of patients received supportive
psychotherapy, and 100% of the reviewed notes explained the treatment rationale and
plan for follow up. Evidence-based care delivered in this program far exceeds the
national norm described in the IOM (2006) report. Statistically significant reductions in
both PHQ-9 score and Distress scores reflect high quality care. Quality care was
delivered similarly across several practice sites and multiple providers.
The CNO and the Director of Quality remained engaged and supportive
throughout the project. The project was viewed as an important quality improvement
initiative for the cancer institute and was adopted as one of the quality studies for the
Cancer Committee and accreditation through the CoC. No significant barriers were
encountered. Availability of outcome data reflecting a significant improvement in PHQ-9
scores from initial assessment has been helpful in reinforcing the importance of
maintaining processes for quality care delivery.
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Strengths and Limitations
This study had a number of methodological strengths and weaknesses. The dual
role of the principle investigator and program provider posed a potential study weakness;
audits to ensure data quality by the PI nurse and Director of Quality minimized this study
risk and interpretation bias. Despite the small sample size, sequential assessment with the
PHQ-9 and delivery of evidence-based interventions seems to be associated with
reduction in depression. The homogeneity of the sample is both a strength and weakness;
study data is primarily relatable to women with breast cancer. Further investigation with
larger samples would be helpful to determine generalizability. Absence of a comparison
group and baseline data poses an additional study limitation.
The clinical setting allowed for significant control of the processes and range of
clinical interventions delivered by program providers. NCIBOP providers sustained
engagement with this initiative and belief in the benefit of consistency among providers;
this may be due to the small size of the department and may take more time to adapt into
larger practice settings. Opportunities continue to exist to enhance front-end processes
with the provision of the PHQ-9 survey to patients upon arrival for appointments.
Recommendations
The implementation of quality and process improvement initiatives provides a
foundation for aggregating department specific outcomes. Study data may be helpful for
establishing benchmarks internally and with other psycho-oncology practices. Multicenter collaboration studies are needed to more clearly understand the unique needs of
specialized patient populations. As the national healthcare agenda continues to evolve,
metric based outcome studies will be necessary to articulate the importance of mental
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health interventions. Continual tracking should ensue beyond the study period to assure
the continuation of evidence-based practice and screening with the PHQ-9. With the
advent of the medical home and further integration of mental health providers into
medical settings, the capacity to fully explain the added value of specialized mental
health services and to advocate for these services is more important than ever before.
Future Research
Future studies with larger samples across multiple cancer centers are needed to
fully understand the impact of sequential assessment of depression with PHQ-9 on
outcomes. Additional study of prevalence and penetrance of psycho-oncology services
within this cancer center may be helpful. Preliminary analysis of the NHANES data
described in this study revealed statistically significant differences in the rates of cancer
patients meeting criterion for major depression when compared to non-cancer patients;
gaps in this area of the literature reinforces the priority for epidemiological study in
psycho-oncology. Additional study evaluating reduction in depression scores and the
impact this has on quality of life are needed.
Conclusions
As bio-medical approaches to treatment continue to advance, psychosocial
interventions supporting quality of life will have to keep pace (IOM, 2007). As the field
of psycho-oncology continues to grow, oncology providers will need to support thorough
psychosocial assessments and psychiatric measures to fully describe patient and program
outcomes. With the inclusion of psychosocial measures for accreditation at the majority
of cancer centers nationwide, cancer centers will be pushed to screen for psychological
sequelae as a routine part of care (COC, 2012; Jacobson, 2012; Jacobson, 2013). Once
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patients enter care with specialized psychiatric providers, the ability to measure outcomes
is important for describing clinical care, advocating for resources, and sustaining
psychiatric programs. Use of the PHQ-9, a reliable and valid measure of depression
severity (Kroneke et al., 2001), at routine intervals in specialized cancer mental health
settings, provides a metric for ongoing analysis of patient outcome data. Evidence
supports the use of validated screenings as a way to minimize treatment variability.
Combined with comprehensive medication management and psychotherapeutic
interventions, patients are likely to have the most optimal outcomes (AHRQ, 2009; NQF,
2011).
Findings from this study are suggestive that the implementation of quality
metrics, sequential assessment with validated tools, and the integration of evidence-based
treatment guidelines are feasible. Aggregation of patient outcome data showed
statistically significant improvement in PHQ-9 scores after intervention with the
NCIBOP providers when using evidence-based treatment approaches. With the evolution
of healthcare policy and a rising demand for quality, the establishment of standards for
care and the inclusion of quality metrics are necessary to effectively measure patient
outcomes.
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Appendix A
Distress Thermometer
SCREENING TOOL FOR MEASURING DISTRESS
Instructions:
First please circle the number (0-10) that best describes how much distress you have been
experiencing in the past week including today.
Extreme distress

No Distress
We want to make sure we are providing you with excellent care. This survey helps us to assess your
needs; if you would like to see either a social worker or Behavioral Oncology provider, please let us
know. You may contact the Behavioral Oncology Program at (502) 899-2673.
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Appendix B
Patient Health Questionnaire (PHQ-9)
Patient Name: _______________________________________

Date: ________

Over the last 2 weeks, how often have you been bothered by any of the following
problems?
(use “✓” to indicate your answer)
Not
Several More than Nearly
at all days ½ the days everyday
1. Little interest or pleasure in doing things
0
1
2
3
2. Feeling down, depressed, or hopeless
0
1
2
3
3. Trouble falling/staying asleep or sleeping too much 0
1
2
3
4. Feeling tired or having little energy
0
1
2
3
5. Poor appetite or overeating
0
1
2
3
6. Feeling bad about yourself – or that you are
0
1
2
3
a failure or have let yourself or your family down
7. Trouble concentrating on things, such as
0
1
2
3
reading the newspaper or watching television
8. Moving or speaking so slowly that other people
0
1
2
3
could have noticed. Or the opposite - being so fidgety
or restless that you have been moving around more
than usual
9. Thoughts that you would be better off dead or of
0
1
2
3
hurting yourself in someway
Add columns
TOTAL
If you checked off any problems, how difficult have these problems made it for you to
do your work, take care of things at home, or get along with other people?
Not difficult at all
Somewhat difficult Very difficult
Extremely difficult
(Healthcare Professional: For interpretation of TOTAL, see accompanying scoring
card).

Running Head: ASSESSING QUALITY OUTCOMES

5
1
Appendix C
Literature Matrix
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Author/
Year
Arroll,
(2010).
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Design
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Sample size
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Results
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Quality of
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Validation of
PHQ-2 & 9
item tools.
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Control
Trial (RCT)
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PHQ-9,
Composite
International
Diagnostic
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Patients
completed
the PHQ-9
and the
CIDI.
Likelihood
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A PHQ-9 score of 10
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detection of
depression.
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Validity,
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Strong
Evidence.

DominguezRafer,
(2011).
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and
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the PHQ-2 &
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Based
Practice
Guideline
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Specificity of
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and
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Cutoff point
>10, pooled
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Limited
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Evidence.
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Quality of
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in CA pt
population.

Needs
additional
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Good
Evidence.

Kroenke,
(2001).

Determine
reliability,
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Study
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3,000 PC pt
and
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clinically
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PHQ-9 is a reliable
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clincally and for
research.

Strengthexternal
validity
supported
through
second study
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Weakness
response bias:
selfadministered
scale.

Level 2,
Good
evidence.
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Design.
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Study on
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severity.
150intervention
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correlation
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were
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PHQ-8 & 9
share
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presence of
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and operating
character.

Description of PHQ9 as a well validated
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most common used
tool in clinical and
research settings

Small sample
size, change in
administration
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Exclusion of
suicide
question in 8
item tool.

Level 2,
Good
evidence.

Manea,
(2012)

Study aimed
to determine
the optimal
cut-off score
for
diagnosing
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Patient
Health
Questionnaire
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Metaanalysis.

PHQ-9

18 validation
studies, 11
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regarding
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properties of
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Pooled
specificity
0.73, variable
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Meta Analysis found
18 studies that
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specificity 73% for
score 10. Sensitivity
variable scores
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some
variability in
study
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Level 1,
Strong
evidence.

Meijer,
(2011)

Assess effect
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on depression
outcomes,
compared
depression

Systematic
Review

Varied by
study.

Pooled
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patients.
Bivariate
metaanalysis to
determine
specificity
and
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positive and
negative
predictive
values.
2,302
studies were
identified to
determine if
screening
impacts

5 of 2,302
were selected
for full article
review.

19 Studies of
screening accuracy, 1
MDD treatment RCT,
No RCT on
depression outcomes.
A gap exists in the

Gap in
literature
around benefit
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Level 1,
Strong
evidence.
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Screening for
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efficacy of
pharmacologi
cal and nonpharm
interventions
for
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cancer
patients.

Study
Design
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Instrument

Sample size
/ Statistics

Results

depression.

Systematic
Review

Tools varied
by study.
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patients
screened
identified
1,908
depressed
patients.

Systematic
Review

Inclusion:
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reviews, metaanalysis,
evidencebased practice
guidelines, or
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observational
trials. All
studies had
outcome

Variable by
study, no
pooled
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provided.
Multiple
statistical
analysis run
due to study
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Conclusions /
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Quality of
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control for
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variables to
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systematic
methodology
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Multiple
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tools, unclear
if best choice
exists.
No systematic
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in place to
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depression or
sequentially
monitor.
Identifies
literature gap;
also Cochrane
review for
depression
management is

Strong
evidence.
Level 1.

literature regarding
the impact of
screening on
depression in cancer
patients.
33 articles
reviewed,
screening
alone did not
improve
depression.
There are no
harms to
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Psychopharm and
therapy are
effective in
older adults.
Limited
information
about
efficacy for
pharmacologi
cal and
psychosocial
interventions
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patients.
Evidence
from study
includes

Organized reveiw of
depression screening.
Encouraged
screening in
situations where it is
possible to have
support and
monitoring of
treatment in patients
who are depressed.

11 trials included
with
pharmacological/
non-pharm
interventions.
Cochrane systematic
review- based on
healthy adults
included.

Strong
evidence.
Level 1.

ASSESSING QUALITY OUTCOMES

First
Author/
Year

Purpose /
Aims

Study
Design

55

Instrument

Sample size
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measure of
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symptoms.
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Recommendations

deductions
made from
healthy
adults.

Limitations

Quality of
evidence

based on
healthy
individuals,
not unique
needs of
cancer
patients.

Thekkumpur
ath, P.
(2011).

Screening for
major
depression in
cancer
outpatients:
the diagnostic
accuracy of
the 9-item
patient health
questionnaire

Systematic
Review

PHQ-9

4,264
pooled
patients.
ROC
analysis.

PHQ-9 with a
cut-off score
of ≥ 8 had
acceptable
sensitivity
and
specificity to
identify
MDD in
cancer
patients.

PHQ-9 is an
acceptable tool for
use in cancer patients
and takes only
approximately 2
minutes to complete.

Thewes &
Greater
Southern
Area Health
Service
Screening
Collaborativ
e (2009).

To determine
feasibility
and
usefulness of
depression
screening in
cancer
outpatient
setting.

Pilot Study

Distress
Thermometer
(DT)

43
participants.
Univariate
and
multivariate
analysis.

44% met
criteria for
having
additional
needs for
psychosocial
care with
validated DT.
86%
sensitivity,

Though screening
with DT did not
increase the number
of referrals, it did
reduce the amount of
time before patients
were offered referral.

Self response
bias. Two
stage process
to determine
presence of
depression
may have
missed cases
of MDD. Was
not inclusive
of all cancer
types. Limited
clinical data to
identify
confounders.
Delayed SCID.
Very small
sample size.

Strong
evidence.
Level 1.

Fair
evidence.
Level 3.
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56
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/ Statistics

Results
77%
specificity.
Screening did
not increase
referral rates,
but did
reduce time
to referral for
specialized
care.

Conclusions /
Recommendations

Limitations

Quality of
evidence
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Quality Improvement Evaluation Plan
Outcome/
Process Indicator

Measure/
Operational Definition

PHQ-9 Questionnaire is
administered to each
patient at initiation of
care with the department.

Percentage of patients with the
principle diagnosis of depression that
has the PHQ-9 documented at time of
initial evaluation.

(Assessment Measure)

Numerator: Number of new patients
who are seen for depression who fill
out the PHQ-9 at the first visit during
a specified time period (example:
January 1 through February 1).

(Long term goal)

Denominator: The number of new
patients seen in the department
during the specified time period with
the diagnosis of depression.

Reassessment with PHQ9

Exclusions: individuals with primary
bipolar disorder, personality disorder
or those who have died (NQF, 2011).
Percentage of patients receiving
treatment with BHONCP who
complete PHQ-9 reassessments.

(Assessment Measure)
(Long term goal)

Numerator: Number of patients seen
for depression in the department who
fill out the PHQ-9 at three-month
follow-up.
Denominator: The number of follow

Rationale for
Measure
Selection
PHQ-9 is a
reliable,
validated and
standardized
tool. The survey
is brief
compared with
other
psychometric
measures.
(Kroenke et al.,
2001; Kroenke,
& Spitzer,
2002; NQF,
2011)

Changes in
score on
standard
psychiatric
rating scale.
This is a
patientcentered
measure, which
also impacts

Data Collection
Approach
The assigned
provider will enter
PHQ-9 data into
the EMR.

Benchmark

Improvement Goal

Internal goal. No
benchmark data is
available in the
cancer patient
population.

Baseline Result: 92%

Internal goal.
No benchmark data
is available in the
cancer patient
population.

Baseline Result: 84%

Goal: Maintain > 90% PHQ-9 entered at
the initial outpatient visit

PI nurse will
complete ongoing
PI with data
analysis and
aggregation
monthly by the
quality director.

The assigned
provider will enter
data into EMR,
making accessible
for data collection.
PI nurse will
complete ongoing
PI with data
analysis and

Goal: Increase to 90% PHQ-9 entered at
follow-up visits

ASSESSING QUALITY OUTCOMES

Outcome/
Process Indicator

Measure/
Operational Definition
up patients who are seen within the
department for depression at three
months.
Exclusions: individuals with primary
bipolar disorder, personality disorder
or those who have died (NQF, 2011).

Patients with Major
Depressive disorder
receive an adequate
medication trial
(Treatment Measure/
Process measure)
(Medium term goal)

Proportion of patients who are
prescribed an antidepressant for
treatment.
Numerator:
Number of patients who meet criteria
for depressive illness who are on a
medication for a specified time
frame.
Denominator: Number of patients
who meet criteria for depression who
are seen by the department during a
specified time frame.
Exclusions: individuals with primary
bipolar disorder, personality disorder
or those who have died (NQF, 2011).
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Rationale for
Measure
Selection
patient safety,
efficiency,
equity and
timeliness
(IOM, 2006).
Engages patient
in symptom
assessment and
treatment
planning.
(IOM, 2001)
Depression is
treatable with
anti-depressant
medication.
Effective and
Equitable care
are two of the
aims of the
IOM report
(2001; 2006).
Ensuring that
patients have
equal access to
medication and
are provided
services based
on knowledge.
A good
evidence level
is described

Data Collection
Approach

Benchmark

Improvement Goal

aggregation
monthly by the
quality director.

Medication is
entered into the
EMR and can be
found on the
patients updated
medication list.
Data collection will
occur through PI
audits of patient
charts to establish
results and identify
practice variances.

Internal goal; no
benchmark data
available.

Diagnosis was recorded on 100% of
patients.
When indicated, medications were
offered and prescribed (89% agreed to
medications).

ASSESSING QUALITY OUTCOMES

Outcome/
Process Indicator

Patients with Major
Depressive disorder
receive Supportive
Psychotherapy or
another validated therapy
modality
(Treatment Measure/
Process Measure)
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Measure/
Operational Definition

Rationale for
Measure
Selection
through the
AHRQ- Level
A rating
(AHRQ, 2009;
Katon &
Schulberg,
1992;
O’Connor et al.,
2009)

Data Collection
Approach

Portion of patients who receive
psychotherapy.

Several types of
psycho-therapy
including
Cognitive
Behavioral
Therapy,
Supportive
Therapy and
Inter-Personal
therapy have
shown efficacy
in the treatment
of depression
(American
Psychiatric
Association
[APA], 2012;
AHRQ, 2012).

The treating
provider will enter
the therapy
modality into the
EMR; data
accessible to the PI
nurse and director
of quality through
the EMR.

Numerator: Number of patients who
receive psychotherapy.
Denominator: Number of patients
with a depression diagnosis seen
within the department during the
specified time frame.

(Medium term goal)
Exclusions: individuals with primary
bipolar disorder, personality disorder
or those who have died (NQF, 2011).

A good
evidence level
is described
through the
AHRQ- Level

Data collection will
occur through PI
audits of patient
charts to establish
results and identify
practice variances
as directed by the
quality team.

Benchmark

Internal goal; no
benchmark data
available.

Improvement Goal

100% of charts reviewed stated delivery
of supportive psychotherapy.

ASSESSING QUALITY OUTCOMES

Outcome/
Process Indicator

Measure/
Operational Definition

Patients report improved
symptom status with
either individual or
combined psychotherapy
and medications

Portion of patients who are receiving
trials on antidepressant therapy with
or without combined psychotherapies
who show improvement in PHQ-9
scores over a specified period of
time.

(Outcome measure)
(Long term goal)

Numerator:
People who show a reduction in
PHQ-9 scores at six months.
Denominator: People who are treated
for six months from initial treatment
for depression who are receiving
psychotherapy with or without
medication management with initial
and six month PHQ-9 scores.

Provider will use PHQ-9
tool to modify treatment
plan if score rises
(Outcome Measure)
(Long term goal)

Exclusions: individuals with primary
bipolar disorder, personality disorder
or those who have died (NQF, 2011).
Portion of patients who are receiving
trials on antidepressant therapy with
or without combined psychotherapies
who show increase in PHQ-9 scores
over a specified period of time.
Numerator:
People who show an increase in
PHQ-9 scores at six months.
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Rationale for
Measure
Selection
A rating
(AHRQ, 2009;
APA, 2012).
This outcome
relates to
patient centered
care, one of the
six quality
domains
identified by the
IOM (2001,
2006).
Additionally
this relates to
the delivery of
effective,
efficient and
safe care as
described by the
IOM; with
integration of
evidence-based
practice (2006).
This relates to
the delivery of
effective,
efficient and
safe care as
described by the
IOM (2006).
This supports
the integration
of evidence-

Data Collection
Approach

Aggregated PHQ-9
scores from initial
through follow ups
available on flow
sheet in EMR.

Benchmark

Internal goal; no
benchmark data
available.

Evidence of
provider
integration of score
and formulation of

Total PHQ-9 mean scores decreased
from 11.34 (6.1) pre-intervention to 8.43
(5.27) post-intervention (p < 0.05).
Patients studied revealed EBP
interventions led to statistically
significant improvement in PHQ-9
scores.

Results will be
aggregated on a
quarterly basis to
capture department
outcomes with
focus on system
improvement,
rather than
individual reports.

Aggregated PHQ-9
scores from initial
through follow ups
available on flow
sheet in EMR.

Improvement Goal

Internal goal; no
benchmark data
available.

100%
Patient charts were reviewed, in patients
where depression scores worsened,
providers made adaptations to the
treatment regimen

ASSESSING QUALITY OUTCOMES

Outcome/
Process Indicator

Measure/
Operational Definition
Denominator: People who are treated
for six months from initial treatment
for depression who are receiving
psychotherapy with or without
medication management with initial
and six month PHQ-9 scores.
Exclusions: individuals with primary
bipolar disorder, personality disorder
or those who have died (NQF, 2011).
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Rationale for
Measure
Selection
based care with
use of
standardized
instruments to
inform care
decisions.

Data Collection
Approach
treatment plan
based on patient
results will be
available in
provider
documentation.
Results will be
aggregated on a
quarterly basis to
capture department
outcomes with
focus on system
improvement,
rather than
individual reports.

Benchmark

Improvement Goal

Running Head: ASSESSING QUALITY OUTCOMES
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Appendix E
Timeline

Process
steps/

Date

DNP Capstone Project
Initial review of
Psycho-oncology
Literature
Preliminary Budget
Identify Gaps in
Psycho-oncology
Engagement of
Clinical Team
Build PHQ-9 into
EMR
Organizational
Assessment
Clinical Microsystem
Assessment
Proposed Evaluation
Plan
Preliminary System
Quality Meetings
Leadership
Engagement in
Proposed Project
Written Goals and
Project Mission
Statement
Finalized Project
Proposal/ Evaluation
Plan
Budgetary Refinement
Meetings with
CNO/Quality and
Clinical Teams
Approval from CNO,
Quality
IRB/NHORA
Approval
Data Collection
Data Analysis
Capstone Paper

First draft integrating
Analysis/ Recs

Capstone paper to
committee for
revisions
Integration of
Revisions
Capstone Presentation
Graduation

November,
2011

April,
2012

October
1, 2012

November,
2012

January 1,
2013

March 1,
2013

April 15,
2013

May 15,
2013

June 1,
2013

July 15,
2013

August 1,
2013

September
30, 2013

October 15,
2013

October 20,
2013

November 1,
2013

November
15November
30, 2013

December,
2013

December
19, 2013

ASSESSING QUALITY OUTCOMES
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Appendix F
Budget
Expense

Office
Supplies

Wages

Survey
Instrument
Total Cost

Item
Quantity
Copies for PHQ9 Scales for
Patients
150
Copies for
Educational
Materials
(Leadership and
Departmental)
200
Mental Health
Quality Resource
Books
2
Subtotal
Manager/ Senior
Leadership
Salaries
Quality
Personnel
Salaries
PI Nurse Salary
Provider Salary
Dollars
EPIC Staff
Salary
Subtotal
PHQ-9
Subtotal

Unit Cost

Total Cost
Monthly

Annualized
Expense

$0.20

$30

$360

$0.20

$40

$480

$60

$120

$120
$960

640

$50

$2667

$32,000

20
120

$45
$32

$75
$320

$900
$3840

50

$62

$258

$3100

40

$35

$117

$1400
$41,240

No Cost

$0

$0

$0
$0
$42,200
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Appendix G
Provider Feedback on PHQ-9 Integration (Focus Group)
1. Do you find the PHQ-9 easy for patients to use?
2. How important do you think it is to administer the PHQ-9 at every patient visit?
3. How important has the PHQ-9 been in guiding treatment decisions?
4. What value do you see in using the PHQ-9 to benchmark with similar programs?
5. Do you think information from the PHQ-9 will be useful in establishing
department guidelines?
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